NKT-Like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors

NKT-Like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors

Therapy with Tyrosine Kinase Inhibitors (TKI) aiming stable deep molecular response is the gold standard to treat Chronic Myeloid Leukemia (CML). NKT-like cells (CD3+CD56+) combine characteristics of T and NK cells. The physiopathological role of these cells remains unknown although the literature r...

Full description

Bibliographic Details
Main Authors: Jani-Sofia Almeida, Patrícia Couceiro, Nelson López-Sejas, Vera Alves, Lenka Růžičková, Raquel Tarazona, Rafael Solana, Paulo Freitas-Tavares, Manuel Santos-Rosa, Paulo Rodrigues-Santos
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-10-01
Series:Frontiers in Immunology
Subjects:
chronic myeloid leukemia
tyrosine kinase inhibitors
NKT-like cells
natural cytotoxicity receptors
immune checkpoints
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.02493/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2019.02493/full

Similar Items